GPC3 and hepatocellular carcinoma: The radiopharmaceutical was prepared by conjugating TJ12P2, a peptide against Glypican-3 (GPC3), expressed in 95% of HCC but rarely present in healthy liver and 2-PMPA, a potent PSMA inhibitor via a PEG linker obtaining the polypeptide T2P.